Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | RPA1 | P27694 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.43 |
| ▸ | BCL2 | P10415 | 3/20 | 0.43 |
| ▸ | MARS1 | P56192 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2912492 | 0.89 | KMT2A (0.54) | KMT2ARPA1MEN1MDM2MCL1 | |
| SCHEMBL2911844 | 0.88 | RPA1 (0.52) | KMT2ARPA1MEN1MDM2MCL1 | |
| SCHEMBL2917043 | 0.87 | TP53 (0.48) | KMT2AMEN1PTGS2 | |
| SCHEMBL2910437 | 0.85 | RPA1 (0.70) | KMT2ARPA1MEN1MDM2MCL1 | |
| SCHEMBL2915954 | 0.84 | MGLL (0.49) | — | |
| SCHEMBL2916975 | 0.82 | KMT2A (0.62) | KMT2ARPA1MEN1MDM2MCL1 | |
| SCHEMBL2910507 | 0.82 | KMT2A (0.56) | KMT2ARPA1MEN1MDM2MCL1 | |
| SCHEMBL13213095 | 0.81 | OXTR (0.39) | KMT2AMEN1PTGS2ABCG2 | |
| SCHEMBL2918250 | 0.81 | RPA1 (0.52) | KMT2ARPA1MEN1MDM2MCL1 | |
| SCHEMBL2909802 | 0.79 | RPA1 (0.49) | KMT2ARPA1MEN1MDM2MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1591443-B1 | PYRAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20060128685-A1 | Pyrazole derivative | DAIICHI PHARMACEUTICAL CO., LTD., (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1591443-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128685-A1 | Pyrazole derivative | PTGS1, PTGS2, PTGER1 | KMT2A 4370/4885RPA1 4200/4885MEN1 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.